CYP4F2 polyclonal, anti-human, mouse, rat
€305.00
In stock
SKU
BS5690
Background:
CYP4F isoforms are involved in the oxidation of important cellular mediators, such as leukotriene B4 (LTB4) and prostaglandins. CYP4F2 catalyzes omega-hydroxylation of LTB4 to a less potent proinflammatory eicosanoid, 20-OH-LTB4 as well as arachidonic acid. CYP4F2 is expressed in liver and kidney. Its expression is repressed by peroxisomal proliferators and induced by retinoic acid. X-linked adrenoleukodystrophy (X-ALD) is a severe neurodegenerative disorder biochemically characterized by elevated levels of very long-chain fatty acids (VLCFA). CYP4F2 participates in the omega-hydroxylation of VLCFAs, which may provide an alternative mode of treatment for X-ALD patients.
Alternative Name:
Leukotriene-B(4) omega-hydroxylase 1, CYPIVF2, Cytochrome P450 4F2, Cytochrome P450-LTB-omega, Leukotriene-B(4) 20-monooxygenase 1
Application Dilution: WB: 1:500~1:1000, IHC: 1:50~1:200, ICC: 1:50~1:200, IP: 1:50~1:200
Specificity: CYP4F2 polyclonal antibody detects endogenous levels of CYP4F2 protein.
Immunogen:
Synthetic peptide, corresponding to amino acids 76-121 of Human CYP4F2.
MW: ~ 60 kDa
Swis Prot.: P78329
Purification & Purity:
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
Format:
1 mg/ml in Phosphate buffered saline (PBS) with 0.05% sodium azide, approx. pH 7.2.
Storage:
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
For research use only, not for use in diagnostic procedure.
CYP4F isoforms are involved in the oxidation of important cellular mediators, such as leukotriene B4 (LTB4) and prostaglandins. CYP4F2 catalyzes omega-hydroxylation of LTB4 to a less potent proinflammatory eicosanoid, 20-OH-LTB4 as well as arachidonic acid. CYP4F2 is expressed in liver and kidney. Its expression is repressed by peroxisomal proliferators and induced by retinoic acid. X-linked adrenoleukodystrophy (X-ALD) is a severe neurodegenerative disorder biochemically characterized by elevated levels of very long-chain fatty acids (VLCFA). CYP4F2 participates in the omega-hydroxylation of VLCFAs, which may provide an alternative mode of treatment for X-ALD patients.
Alternative Name:
Leukotriene-B(4) omega-hydroxylase 1, CYPIVF2, Cytochrome P450 4F2, Cytochrome P450-LTB-omega, Leukotriene-B(4) 20-monooxygenase 1
Application Dilution: WB: 1:500~1:1000, IHC: 1:50~1:200, ICC: 1:50~1:200, IP: 1:50~1:200
Specificity: CYP4F2 polyclonal antibody detects endogenous levels of CYP4F2 protein.
Immunogen:
Synthetic peptide, corresponding to amino acids 76-121 of Human CYP4F2.
MW: ~ 60 kDa
Swis Prot.: P78329
Purification & Purity:
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
Format:
1 mg/ml in Phosphate buffered saline (PBS) with 0.05% sodium azide, approx. pH 7.2.
Storage:
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
For research use only, not for use in diagnostic procedure.
| Is Featured? | No |
|---|
Write Your Own Review